Amylin Plans Cardiac Safety Study By The Book After Bydureon Rejection
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
There’s more than meets the eye to the story of the seemingly surprising “complete response” letter for Amylin’s ultra-high-profile once-weekly diabetes injectable Bydureon.